Tamil Nadu: Mortal remains of former ISRO scientist Nellai Su Muthu brought to Madurai
Madurai (Tamil Nadu) [India], June 17 (ANI): The mortal remains of ISRO's former scientist Nellai Su Muthu were brought to Madurai for public homage on Tuesday.
Nellai Su. Muthu (74) passed away in Kerala's Thiruvananthapuram on June 16 due to ill health.
He had served as a senior scientist at the Sriharikota Satish Dhawan Space Centre.
PV Venkitakrishnan, a former director at ISRO in a social media post said that Muthu was a renowned scientist, science writer, and author of over 70 books on various topics, including science, children's literature, poetry, history, translation, and criticism.
Some notable works include 'Sevvayil Ulvetkkaiyum Nal Vaaippum' (Exploration and Fortune in Mars), exploring Greek myths and modern scientific possibilities about Mars. His 'Vinveli 2057' (SKY 2057), had won the best book award in Mathematics, Astronomy, Physics, and Chemistry categories for 2000
'Arivuttum Vigyaana Vilaiyaatu' (Science Tricks That Provide Knowledge), won the best book award in Children's Literature category for 2004. 'Einsteinum Andaveliyum' (Einstein and Space), had won the best book award in Biography and Personal History categories for 2005.
Muthu, said the former ISRO director had worked as a senior scientist at the Satish Dhawan Space Centre in Sriharikota and collaborated with former President APJ Abdul Kalam.
He received several awards, including the Kavimamani Award from the World Tamil Poets Association of Malaysia and the Best Book Award from the Tamil Development Department of the Government of Tamil Nadu.
'A life dedicated to spreading science and scientific awareness in a language which common man can understand,' Venkitakrishnan said in his post adding 'Pranams to my friend.' (ANI)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysia Sun
5 days ago
- Malaysia Sun
Tamil Nadu: Mortal remains of former ISRO scientist Nellai Su Muthu brought to Madurai
Madurai (Tamil Nadu) [India], June 17 (ANI): The mortal remains of ISRO's former scientist Nellai Su Muthu were brought to Madurai for public homage on Tuesday. Nellai Su. Muthu (74) passed away in Kerala's Thiruvananthapuram on June 16 due to ill health. He had served as a senior scientist at the Sriharikota Satish Dhawan Space Centre. PV Venkitakrishnan, a former director at ISRO in a social media post said that Muthu was a renowned scientist, science writer, and author of over 70 books on various topics, including science, children's literature, poetry, history, translation, and criticism. Some notable works include 'Sevvayil Ulvetkkaiyum Nal Vaaippum' (Exploration and Fortune in Mars), exploring Greek myths and modern scientific possibilities about Mars. His 'Vinveli 2057' (SKY 2057), had won the best book award in Mathematics, Astronomy, Physics, and Chemistry categories for 2000 'Arivuttum Vigyaana Vilaiyaatu' (Science Tricks That Provide Knowledge), won the best book award in Children's Literature category for 2004. 'Einsteinum Andaveliyum' (Einstein and Space), had won the best book award in Biography and Personal History categories for 2005. Muthu, said the former ISRO director had worked as a senior scientist at the Satish Dhawan Space Centre in Sriharikota and collaborated with former President APJ Abdul Kalam. He received several awards, including the Kavimamani Award from the World Tamil Poets Association of Malaysia and the Best Book Award from the Tamil Development Department of the Government of Tamil Nadu. 'A life dedicated to spreading science and scientific awareness in a language which common man can understand,' Venkitakrishnan said in his post adding 'Pranams to my friend.' (ANI)
Malaysian Reserve
13-06-2025
- Malaysian Reserve
Illuccix® Prostate Cancer PSMA-PET Imaging Agent Approved in Greece
MELBOURNE, Australia, June 13, 2025 /PRNewswire/ –Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by the Greek EOF[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer – a broad clinical label. This approval enhances the options available to healthcare providers across Greece for PSMA-PET[3] imaging using a clinically-validated, gallium-based radiopharmaceutical. Illuccix, after radiolabelling with gallium-68, is indicated in Greece for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. PSMA-PET imaging represents a significant advancement in prostate cancer management, providing clinicians with more information than conventional imaging methods (bone scan, CT[4] scan) thereby offering a new standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR[5]. Illuccix PSMA-PET will help fulfil a critical unmet need by facilitating access to timely and effective diagnosis and patient selection for treatment with PSMA-targeted therapy. Access to PSMA-PET imaging in Greece remains extremely limited. During 2024, tracer and staff shortages meant that only 1,600 PSMA-PET examinations were conducted nationally, representing a small fraction of the 7,000 patients newly diagnosed each year. Illuccix's broad approval, supported by robust clinical data including the largest Ga-68-based PSMA data set from the VISION trial[6], will help address these challenges. Dr. Theodore Pipikos, Head of Nuclear Medicine and PET/CT at Hygeia Hospital, Athens, welcomed the decision, commenting, 'The approval of Illuccix marks a significant step forward in prostate cancer imaging for men in Greece. Given the structural barriers in our healthcare system, Illuccix provides healthcare practitioners with a widely accessible and much-needed tool to improve diagnostic accuracy.' Raphaël Ortiz, Chief Executive Officer, Telix International, added, 'The approval of Illuccix in Greece will support more widely available PSMA-PET imaging, and enable more healthcare providers and their patients to benefit from the convenience and flexibility of generator-produced gallium. This milestone reinforces Telix's ongoing commitment to advancing prostate cancer care and expanding access to innovative diagnostic and therapeutic radiopharmaceuticals across Europe'. Illuccix will be made available in Greece through Telix's distribution partner BIOKOSMOS S.A. a key radiopharmaceutical manufacturer in Greece with a comprehensive distribution network, which covers the full Greek Territory as well as Cyprus. Healthcare professionals in Greece interested in ordering Illuccix or learning more about availability can contact orders@ or call +30 22920 63900. Prostate Cancer in Greece Prostate cancer is the most common cancer for men in Greece with over 7,000 new cases diagnosed annually, and a significantly higher incidence in men than either bowel cancer (4,346 new cases) or lung cancer (6,357 new cases). Prostate cancer is the third most common cause of cancer death in men in Greece, with just over 1,900 men dying from their disease in 2022[7]. About Illuccix Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[8], by the Australian Therapeutic Goods Administration (TGA)[9], by Health Canada[10], by the Brazilian Health Regulatory Agency (ANVISA)[11], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[12], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[13], by the German Federal Institute for Drugs and Medical Devices (BfArM), and in multiple countries within the European Economic Area (EEA)[14] following a positive decentralized procedure (DCP) opinion by the German medical regulator[15]. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Positron emission tomography. [2] ΕΟΦ, Εθνικός Οργανισμός Φαρμάκων (National Organization for Medicines). [3] Imaging of prostate-specific membrane antigen with positron emission tomography. [4] Computed tomography. [5] EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: [6] ID: NCT03511664. VISION study sponsored by Endocyte, a Novartis company. Telix provided Illuccix (TLX591-CDx) for PSMA-PET imaging. [7] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024. [8] Telix ASX disclosure 20 December 2021. [9] Telix ASX disclosure 2 November 2021. [10] Telix ASX disclosure 14 October 2022. [11] Telix ASX disclosure 18 March 2025. [12] Telix ASX disclosure 13 February 2025. [13] Telix media release 29 April 2025. [14] Czech Republic, Denmark, Finland, Greece, Ireland, Luxembourg, Malta, the Netherlands, Norway, Portugal and Sweden at time of release. [15] Telix ASX disclosure 17 January 2025. Logo – View original content:
Malaysia Sun
12-06-2025
- Malaysia Sun
Navy Chief Admiral Tripathi meets with wireless tech pioneer Paulraj, discusses strengthening ecosystem for AI
New Delhi [India], June 12 (ANI): Chief of the Naval Staff (CNS), Admiral Dinesh K Tripathi, interacted with Commodore Arogyaswami Paulraj (retd) on issues and initiatives related to strengthening the ecosystem for Artificial intelligence (AI) and semiconductors, indigenisation of defence systems, and infusion of technology. Coimbatore-born Commodore Paulraj who jointed the Stanford University faculty after serving in the Indian Navy for 26 years is a pioneer of the APSOH SONAR system and inventor of MIMO technology. Before interacting with the CNS, Commodore Paulraj (retd) also addressed senior officers of the Indian Defence Forces on AI and Core Technologies in Modern Warfare and National Security at Nausena Bhawan on Wednesday. Drawing from his distinguished naval R&D career, including the development of the APSOH SONAR system and contributions to semiconductor and electronics systems, Comomdore Paulraj emphasised the urgent need to invest in indigenous capabilities for data processing, autonomous systems, and AI-enabled platforms. Globally renowned for inventing MIMO (Multiple-Input Multiple-Output) antenna technology - now foundational to 4G, 5G, and Wi-Fi - he underscored the strategic necessity of integrating AI into the Indian military ecosystem. His talk highlighted that self-reliance in core technologies is no longer a choice, but a national imperative aligned with the goals of Aatmanirbhar Bharat and ViksitBharat 2047, the Indian Navy said in a statemement.. Meanwhile, on Wednesday, the Indian Navy delegation, led by Rear Admiral Shantanu Jha, NM, participated in the 10th Navy-to-Navy Staff Talks with the Royal Malaysian Navy held in Kuala Lumpur on June 10. The Royal Malaysian Navy delegation was led by First Admiral Harisundar Rajoo, Senior Director, Operations and Training. During the talks, both sides discussed ongoing bilateral naval engagements and outlined plans for future collaborative activities. The Indian Navy, in a post on X, stated, 'Rear Admiral Shantanu Jha, NM, led the #IndianNavy delegation for the 10th Navy to Navy Staff Talks with the #RoyalMalaysianNavy, at Kuala Lumpur on 10 June. The #RoyalMalaysianNavy delegation was led by First Admiral Harisundar Rajoo, Senior Director, Operations and Training. Both sides held discussions on ongoing bilateral naval engagements and outlined plans for future collaborative activities.' In parallel to the naval dialogue in Kuala Lumpur, India also expanded its diplomatic outreach in the region. Secretary (East) P. Kumaran met Permanent Secretary, Brunei Darussalam's Ministry of Foreign Affairs, Hajah Johariah Binti Abdul Wahab, on the sidelines of the East Asia Summit Senior Officials' Meeting (EAS SOM) in Malaysia's Penang on Tuesday. During the meeting, the two sides discussed ways to further deepen the enhanced partnership between India and Brunei and cooperation under ASEAN and other frameworks.(ANI)
